At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
vilobelimabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Exploratory Phase IIa Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Patients With Pyoderma Gangrenosum (OPTIMA)
In Brief
A Phase 2 clinical trial evaluating vilobelimab for Pyoderma Gangrenosum. Completed, enrolled 19 participants across 10 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPyoderma Gangrenosum
CountriesCanada, Poland, United States
CollaboratorsInnovaderm Research Inc.
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedJun 2019
Primary CompletionJan 2022
TodayJul 2026
First PostedJun 3, 2019
Enrollment StartMay 16, 2019
Primary CompletionJan 3, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.1 years ago
Interventions
vilobelimabdrug
IV infusions of vilobelimab diluted in sodium chloride.